Tweet This study indicates that rates of brain atrophy are affected by age and that they should be considered. One thinks that would be wise, but one wonders what this would do to the powering of studies (i.e. how big they have to be to…
Tweet This morning I woke up like someone has been punching me in the arm all night and guess it is all related to neck problems but it is part of that dropping to bits as you get older thing. Toss on top of this…
Researchers have developed a mouse model designed to reflect the disability worsening that occurs in the absence of relapses for many people with multiple sclerosis (MS). The model shows key features of this form of disease worsening, known as progression independent of relapse activity (PIRA),…
When living with a chronic illness like multiple sclerosis, building a community for yourself of people who truly get it is incredibly valuable. Having a support network in your life of people who are there for you in easy times … Continue reading → Source:…
Tweet We can see the people making CD20 depleting antibodies and they want to position themselves versus the other antibodies and the other drugs. If you are a fantastic inhibitor of the immune response, it is likely that you will increase the risk of infection.…
I’ve been missing from these pages and it feels like losing a limb. Words are usually more reliable for me. They don’t normally let me down. I don’t like it. I’ve lost interest in writing about my disease. It’s become boring to me. It never…
Now that the holiday season, with all its decadent meals, is over, I wanted to share an update on the diet I mentioned in a column last September. At the time, I was still in the elimination phase of a FODMAP diet (which stands for…
Happy Friday Eve, y’all! I hope you are doing well, and the week has treated you well. It has been a while since my last post, and I had promised myself I would write more, but too many things have gotten in the way. When…
A three-year study of GA Depot, a monthly injection for primary progressive multiple sclerosis (PPMS), found that most patients experienced no disability progression, with some even showing slight improvements in mobility. These interim results from a Phase 2a clinical trial will be presented tomorrow by…
Researchers and clinicians are gathering in San Diego and online for the 11th annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, a three-day meeting focused on multiple sclerosis (MS) research and care. ACTRIMS 2026, being held Feb. 5-7 at the Marriott…